X

Trial Profile

A single arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL) Revised protocol 03a, including amendment 04 and 05

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Jan 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Follicular lymphoma; Non-Hodgkin's lymphoma
Focus Therapeutic Use
Acronyms CheckMate140
Sponsors Bristol-Myers Squibb

Most Recent Events

13 Dec 2021 Status changed from active, no longer recruiting to completed.
29 Aug 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
21 Jan 2021 Planned number of patients changed from 90 to 115.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com